Targeting KRAS is crucial because mutations in this gene are some of the most common and challenging to treat in cancer. For many years, KRAS was considered "undruggable" due to the structure of the protein and its high affinity for GTP/GDP. However, recent advancements have made it possible to develop drugs that specifically target mutant KRAS proteins, opening new avenues for cancer treatment.
